What are GIP receptor agonists?

GIP receptor agonists mimic a natural gut hormone called glucose-dependent insulinotropic peptide (GIP). They help regulate blood sugar, support insulin release, and influence appetite control. Some newer treatments, like Mounjaro, combine GIP with GLP-1 activity. These medications can offer dual support for weight management and metabolic health.

In this post, we explain what GIP receptor agonists are, how they work in the body, and how they compare to GLP-1 medications for weight loss and diabetes management.

Key points

• GIP receptor agonists help regulate appetite, insulin response, and blood sugar.
• Some treatments, like Mounjaro, combine GIP and GLP-1 activity to support greater weight loss and metabolic improvements.
• These medications work best when paired with sustainable lifestyle changes and clinical guidance.

What does GIP mean?

GIP stands for ‘glucose-dependent insulinotropic peptide’ and is part of a group of hormones called incretins.

GIP helps regulate blood sugar by encouraging insulin secretion and supporting your body's ability to use glucose effectively.

It also influences appetite signaling, helping you regulate your appetite. This is one of the ways GIP receptor agonists can help with weight loss.

How do GIPs work?

GIP receptor agonists mimic the action of the natural GIP hormone in your body. They bind to GIP receptors. When this happens, they trigger responses that help regulate blood sugar, insulin, and appetite.

By activating these receptors, treatments containing GIP agonists can support your body's ability to manage glucose more effectively. They may help reduce the hunger signals that can lead to overeating.

Mechanism of action

GIP receptor agonists increase insulin secretion from your pancreas if you have high blood sugar levels This glucose-dependent response helps improve blood sugar control without causing low blood sugar (hypoglycaemia).

They also reduce the release of glucagon, which is a hormone that raises blood sugar. This combined effect supports more stable blood sugar levels throughout the day.

Some treatments containing GIP agonists may slow gastric emptying. This means food moves more slowly from your stomach into your small intestine. This can help you feel fuller for longer and support appetite control.

GIP receptor agonists can also influence your satiety and energy balance by affecting how your body processes food and stores energy. This can support your weight management goals, especially when combined with lifestyle changes.

What treatments use GIP activity?

The most well-known treatment with GIP activity is tirzepatide, which is marketed under the brand name Mounjaro. Tirzepatide is a dual agonist and targets both GIP and GLP-1 receptors for broader metabolic support.

Mounjaro is a prescription-only treatment that supports weight management and blood sugar control. It may benefit people living with type 2 diabetes or those with a higher BMI and weight-related health conditions.

Qualified healthcare professionals should always oversee treatments like Mounjaro. These medications are most effective when you also prioritise a healthy diet and increased exercise.

How do GIP receptor agonists aid weight loss?

GIP receptor agonists support weight loss in several ways:

• Appetite regulation can help you feel fuller for longer by influencing satiety signals and slowing digestion. This can reduce the urge to snack between meals.
• Reduced calorie intake often follows naturally when appetite is better controlled. This can make it easier to maintain a calorie deficit without always feeling hungry.
• Improved insulin sensitivity helps your body use glucose more effectively. This can support metabolic health and reduce fat storage over time. Better insulin function is particularly beneficial for people with insulin resistance or type 2 diabetes.
• Blood sugar stability supported by GIP medications can help reduce energy crashes and cravings. As a result, it may be easier to avoid reactive eating or high-sugar foods.

And the benefits of GIP receptor agonists can go beyond the number on your scales. For example, some patients see improved heart health and a reduced risk of other weight-related complications.

Is Mounjaro a GIP?

Mounjaro is a dual agonist, meaning it targets both GIP and GLP-1 receptors. By activating both pathways, Mounjaro can support insulin release, appetite control, and blood sugar regulation more comprehensively. Clinical evidence suggests dual agonists may support greater weight loss and other health improvements compared to GLP-1-only treatments.

How do GIPs compare to GLP-1s?

GIP and GLP-1 receptor agonists work through similar but distinct mechanisms. Both help regulate blood sugar and support weight loss. However, they target different hormone receptors and offer slightly different benefits.

GLP-1 medications have been used longer. They also have more extensive clinical data supporting their use for weight management and diabetes care.

Medications that include GIP receptor activity are newer. Dual-action treatments like tirzepatide combine both pathways for potentially greater effectiveness.

GLP-1 and GIP comparison table

Both treatment types work best when paired with structured lifestyle support, including balanced nutrition and regular physical activity. The best option will depend on your individual health needs, eligibility criteria, and clinical guidance from your healthcare providers.

Frequently asked questions

Are GIP receptor agonists safe?

Approved dual GIP/GLP-1 receptor agonists are generally considered safe when prescribed and monitored by healthcare professionals. Like all medications, they can cause side effects in some people. These side effects typically include digestive symptoms like nausea, vomiting, or diarrhoea.

Your healthcare provider will assess whether this treatments is suitable based on your medical history, current health, and any other medications you take.

Are treatments using GIP activity approved for weight loss?

Tirzepatide (Mounjaro) is approved for weight management in adults with:

• a BMI of 30 or above
• a BMI 27 or above with at least one weight-related health condition
• type 2 diabetes

Approval and prescribing criteria may vary depending on your healthcare system. Your clinician will determine whether you meet eligibility requirements.

Who can take GIP receptor agonists?

GIP receptor agonists are suitable for adults who meet specific clinical criteria. This typically includes:

• people with a higher BMI who have weight-related health conditions
• those living with type 2 diabetes who need additional support managing blood sugar and weight

These medications aren’t the right fit for everyone. Your healthcare provider will assess factors like your medical history, current medications, and any contraindications before prescribing GIP treatments.

Do treatments containg GIP agonists have side effects?

Yes, GIP medications can cause side effects in some people. The most common side effects are digestive and include:

• nausea
• vomiting
• diarrhoea
• constipation
• reduced appetite

These symptoms are typically mild to moderate. They often improve as your body adjusts to treatment. Starting with a lower dose and gradually increasing can help minimise side effects.

More serious side effects are uncommon but possible. You should seek medical advice if you experience:

• severe abdominal pain
• persistent vomiting
• signs of an allergic reaction

Are GIP receptor agonists better than GLP-1s?

Dual GIP/GLP-1 agonists may support greater weight loss and other health improvements compared to GLP-1-only treatments. However, individual responses vary. Neither option is universally ‘better’ and the most suitable treatment depends on your specific health needs, medical history, and treatment goals.

Your healthcare provider can help determine which medication is best for you. They’ll consider clinical evidence, your eligibility, and how well you tolerate treatment.

How quickly do treatments containing GIP agonists work?

Weight loss with treatments containing GIP agonists typically begins within the first few weeks of treatment. Most people see gradual, progressive weight loss over several months. Progress is often easier to see patients increase their dose and maintain lifestyle changes. Results vary depending on each individual.

Blood sugar improvements may happen sooner. Sometimes, patients notice improvements within the first few weeks of treatment. Consistency with medication, nutrition, and physical activity supports the best long-term outcomes.

Can GIP treatments improve insulin resistance?

GIP receptor agonists can help improve insulin sensitivity by supporting better insulin secretion and reducing glucagon levels. This may benefit people with insulin resistance or type 2 diabetes.

However, these medications should be part of a comprehensive treatment plan. Lifestyle changes and ongoing clinical monitoring are both essential.

Summary of GIPs

"GIP receptor agonists represent an important development in weight management and diabetes care. Dual-action treatments like Mounjaro work with your body's natural hormone systems. They can support appetite control, blood sugar regulation, and gradual weight loss.

“These medications can be highly effective when combined with sustainable lifestyle changes and ongoing support from healthcare professionals. Our clinicians can assess your suitability. We can help you understand how it might fit into your overall health plan."

Niya Mansuri, weight loss expert at myBMI

Sources

• Considerations and interactions with GLP-1 receptor agonists. (2025) NHS Specialist Pharmacy Service. [Accessed 20 February 2026]
• Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials. (2025) National Library of Medicine. [Accessed 20 February 2026]
• GLP-1 drugs: should the NHS roll them out at scale? (2025) The King's Fund. [Accessed 20 February 2026]
• GLP-1 receptor agonists. (2025) Diabetes UK. [Accessed 20 February 2026]
• GLP-1 injections for weight loss and diabetes. (n.d.) NHS Topsham Surgery. [Accessed 20 February 2026]
• How long does it take for GLP-1s to suppress appetite? (2025) Cleveland Clinic. [Accessed 20 February 2026]
• Weight management injections. (n.d.) NHS England. [Accessed 20 February 2026]